Vol 26, No 5 (2021)
Research paper
Published online: 2021-08-13

open access

Page views 6315
Article views/downloads 400
Get Citation

Connect on Social Media

Connect on Social Media

Outcomes and computed tomography radiomic features extraction in soft tissue sarcomas treated with neoadjuvant radiation therapy

Javier González-Viguera1, Gabriel Reynés-Llompart2, Alicia Lozano1
Rep Pract Oncol Radiother 2021;26(5):804-813.

Abstract

Background: The aim of the study was to evaluate the management, toxicity and treatment responses of patients treated with neoadjuvant radiotherapy (NART) for soft tissue sarcomas (STS) and to analyse the potential of radiomic features extracted from computed tomography (CT) scans.

Materials and methods: This is a retrospective and exploratory study with patients treated between 2006 and 2019. Acute and chronic toxicities are evaluated. Local progression free survival (LPFS), distant progression free survival (DPFS) and overall survival (OS) are analysed. Radiomic features are obtained.

Results: A total of 25 patients were included. Median follow-up is 24 months. Complications in surgical wound healing were observed in 20% of patients, chronic fibrosis was documented as grade 1 (12%) and grade 2 (12%) without grade 3 events and chronic lymphedema as grade 1 (8%) and grade 2 (20%) without grade 3 events. Survival variables were LPFS 76%, DPFS 62% and OS 67.2% at 2-year follow-up. CT radiomics features were associated significantly with local control (GLCM-correlation), systemic control (HUmin, HUpeak, volume, GLCM-correlation and GLZLM-GLNU) and OS (GLZLM-SZE).

Conclusions: STS treated with NART in our centre associate with an OS and toxicity comparable to other series. CT radiomic features have a prognosis potential in STS risk stratification. The results of our study may serve as a motivation for future prospective studies with a greater number of patients.

Article available in PDF format

View PDF Download PDF file

References

  1. Garcia del Muro X, de Alava E, Artigas V, et al. Spanish Group for Research on Sarcoma. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemother Pharmacol. 2016; 77(1): 133–146.
  2. Burningham Z, Hashibe M, Spector L, et al. The epidemiology of sarcoma. Clin Sarcoma Res. 2012; 2(1): 14.
  3. Jo VY, Fletcher CDM. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014; 46(2): 95–104.
  4. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982; 196(3): 305–315.
  5. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002; 359(9325): 2235–2241.
  6. Al-Absi E, Farrokhyar F, Sharma R, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol. 2010; 17(5): 1367–1374.
  7. Sampath S, Schultheiss TE, Hitchcock YJ, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients. Int J Radiat Oncol Biol Phys. 2011; 81(2): 498–505.
  8. Alektiar KM, Brennan MF, Healey JH, et al. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol. 2008; 26(20): 3440–3444.
  9. Callegaro D, Miceli R, Mariani L, et al. Soft tissue sarcoma nomograms and their incorporation into practice. Cancer. 2017; 123(15): 2802–2820.
  10. Naghavi A, Yang G, Latifi K, et al. The Future of Radiation Oncology in Soft Tissue Sarcoma. Cancer Control. 2018; 25(1): 107327481881550.
  11. Tanaka K, Ozaki T. New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol. 2019; 49(2): 103–107.
  12. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Publish Date: November 27, 2017. . https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
  13. Nioche C, Orlhac F, Boughdad S, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018; 78(16): 4786–4789.
  14. IBM Corp. IBM SPSS Statistics for Windows, Version 25.0. Released 2017.
  15. PyRadiomics Community. http://github.com/radiomics/pyradiomics.
  16. O'Sullivan B, Griffin AM, Dickie CI, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013; 119(10): 1878–1884.
  17. Peeken JC, Bernhofer M, Spraker MB, et al. CT-based radiomic features predict tumor grading and have prognostic value in patients with soft tissue sarcomas treated with neoadjuvant radiation therapy. Radiother Oncol. 2019; 135: 187–196.